Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2020 Apr 15

PMID 32284951

Citations 149

Authors

Erin K McCreary

Jason M Pogue

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.

Citing Articles

A narrative review on adverse drug reactions of COVID-19 treatments on the kidney.

Jahanshahi F, Jazayeri S, Eraghi M, Reis L, Hamidikia M, Amiri S Open Med (Wars). 2024; 19(1):20230867.

PMID: 38584847 PMC: 10996932. DOI: 10.1515/med-2023-0867.

The role of N-acetylcysteine in decreasing neutrophil-lymphocyte ratio in COVID-19 patients: A double-blind, randomized controlled trial.

Prabowo N, Megantara M, Apriningsih H Narra J. 2024; 3(2):e121.

PMID: 38454976 PMC: 10919724. DOI: 10.52225/narraj.v3i2.121.

A Review on Role of Inflammation in Coronavirus Disease.

Lotfi A, Hajian P, Abbasi L, Gargari M, Fard N, Naderi D Endocr Metab Immune Disord Drug Targets. 2024; 24(13):1488-1505.

PMID: 38303532 DOI: 10.2174/0118715303265274231204075802.

Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise.

Janoff E, Brown S, Belitskaya-Levy I, Curtis J, Bonomo R, Miller E Contemp Clin Trials Commun. 2023; 35:101190.

PMID: 37560085 PMC: 10407261. DOI: 10.1016/j.conctc.2023.101190.

Unknown adverse drug reactions from spontaneous reports in a hospital setting: characterization, follow-up, and contribution to the pharmacovigilance system.

Filippi-Arriaga F, Aguilera C, Guillen E, Bellas L, Perez E, Vendrell L Front Pharmacol. 2023; 14:1211786.

PMID: 37492089 PMC: 10364048. DOI: 10.3389/fphar.2023.1211786.

References

Kotch C, Barrett D, Teachey D . Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019; 15(8):813-822. PMC: 7936577. DOI: 10.1080/1744666X.2019.1629904. View

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

Gamino-Arroyo A, Guerrero M, McCarthy S, Ramirez-Venegas A, Llamosas-Gallardo B, Galindo-Fraga A . Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clin Infect Dis. 2019; 69(11):1903-1911. PMC: 6853643. DOI: 10.1093/cid/ciz100. View

Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C . Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014; 14(7):609-18. PMC: 7164783. DOI: 10.1016/S1473-3099(14)70717-0. View

Lopez Aspiroz E, Santos Buelga D, Figueroa S, Lopez Galera R, Ribera Pascuet E, Hurle A . Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. Ther Drug Monit. 2011; 33(5):573-82. DOI: 10.1097/FTD.0b013e31822d578b. View

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

Arabi Y, Mandourah Y, Al-Hameed F, Sindi A, Almekhlafi G, Hussein M . Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2017; 197(6):757-767. DOI: 10.1164/rccm.201706-1172OC. View

Lee N, Chan K, Hui D, Ng E, Wu A, Chiu R . Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4):304-9. PMC: 7108318. DOI: 10.1016/j.jcv.2004.07.006. View

Chan K, Lai S, Chu C, Tsui E, Tam C, Wong M . Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6):399-406. View

10.

Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View

11.

Stevens M, Patel P, Nori P . Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck. Infect Control Hosp Epidemiol. 2020; 41(6):744-745. PMC: 7137534. DOI: 10.1017/ice.2020.69. View

12.

OKeefe B, Giomarelli B, Barnard D, Shenoy S, Chan P, McMahon J . Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 2009; 84(5):2511-21. PMC: 2820936. DOI: 10.1128/JVI.02322-09. View

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

14.

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

15.

Arabi Y, Asiri A, Assiri A, Jokhdar H, Alothman A, Balkhy H . Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020; 21(1):8. PMC: 6942374. DOI: 10.1186/s13063-019-3846-x. View

16.

Wang Z, Chen X, Lu Y, Chen F, Zhang W . Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020; 14(1):64-68. DOI: 10.5582/bst.2020.01030. View

17.

Auyeung T, Lee J, Lai W, Choi C, Lee H, Lee J . The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005; 51(2):98-102. PMC: 7132384. DOI: 10.1016/j.jinf.2004.09.008. View

18.

Song Y, Yao C, Yao Y, Han H, Zhao X, Yu K . XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med. 2019; 47(9):e735-e743. PMC: 6727951. DOI: 10.1097/CCM.0000000000003842. View

19.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

20.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View